CoChat

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Open access
Patnaik, Akash, Swanson, Kenneth D., Csizmadia, Eva, Solanki, Aniruddh, Landon-Brace, Natalie, Gehring, Marina P., Helenius, Katja, Olson, Brian M., Pyzer, Athalia R., Wang, Lily C., Elemento, Olivier, Novak, Jesse, Thornley, Thomas B., Asara, John M., Montaser, Laleh, Timmons, Joshua J., Morgan, Todd M., Wang, Yugang, Levantini, Elena, Clohessy, John G., Kelly, Kathleen, Pandolfi, Pier Paolo, Rosenblatt, Jacalyn M., Avigan, David E., Ye, Huihui, Karp, Jeffrey M., Signoretti, Sabina, Balk, Steven P., Cantley, Lewis C. · 2017 · Cancer Discovery
Cited by 146

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine kinase inhibitor cabozantinib showed striking responses in cancer clinical trial patients across several malignancies. Here, we show that cabozantinib rapidly eradicates invasive, poorly differentiated PTEN/p53-deficient murine prostate cancer. This was associated with enhanced release of neutrophil chemotactic factors from tumor cells, including CXCL12 and HMGB1, resulting in robust infiltration of neutrophils into the tumor. Critically, cabozantinib-induced tumor clearance in mice was abolished by antibody-mediated granulocyte depletion or HMGB1 neutralization or blockade of neutrophil chemotaxis with the CXCR4 inhibitor plerixafor. Collectively, these data demonstrate that cabozantinib triggers a neutrophil-mediated anticancer innate immune response, resulting in tumor clearance. Significance: This study is the first to demonstrate that a tyrosine kinase inhibitor can activate neutrophil-mediated antitumor innate immunity, resulting in invasive cancer clearance. Cancer Discov; 7(7); 750–65. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 653

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-16-0778

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 146

Metadata

Authors
Patnaik, A., Swanson, K. D., Csizmadia, E., Solanki, A., Landon-Brace, N., Gehring, M. P., Helenius, K., Olson, B. M., Pyzer, A. R., Wang, L. C., Elemento, O., Novak, J., Thornley, T. B., Asara, J. M., Montaser, L., Timmons, J. J., Morgan, T. M., Wang, Y., Levantini, E., Clohessy, J. G., Kelly, K., Pandolfi, P. P., Rosenblatt, J. M., Avigan, D. E., Ye, H., Karp, J. M., Signoretti, S., Balk, S. P., & Cantley, L. C.
Venue
Cancer Discovery
Published
2017-07-01
Volume
7
Issue
7
Pages
750-765
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2592811353
Cited by
146
References
7
FWCI
4.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. https://app.cochat.ai/papers/10.1158/2159-8290.cd-16-0778
The paper
Patnaik, A., Swanson, K. D., Csizmadia, E., Solanki, A., Landon-Brace, N., Gehring, M. P., Helenius, K., Olson, B. M., Pyzer, A. R., Wang, L. C., Elemento, O., Novak, J., Thornley, T. B., Asara, J. M., Montaser, L., Timmons, J. J., Morgan, T. M., Wang, Y., Levantini, E., . . . Cantley, L. C. (2017). Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-16-0778

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.